NLRP3 inflammasome in health and disease. Med Int Méx 2025; 41 (8): 498-511. https://doi.org/10.24245/mim.v41i8.10153 Alain Raimundo Rodríguez Orozco,1 Samara Ocegueda González,2 Juan Carlos Galán Cruz,2 Brenda Guadalupe Barrientos Rodríguez,2 Jareth Lucila Montelongo Ortega,2 Martha Estrella García Pérez1…
Effectiveness and safety of hormonal therapy in patients with gender dysphoria: A systematic literature review. Med Int Méx 2025; 41 (8): 487-497. https://doi.org/10.24245/mim.v41i8.10069 Juan Alzate,1 Pedro Herrera Calle,1 Kevin Alexander Mosquera Restrepo,2 Danilo Alejandro Solarte…
Analysis of therapeutic options for aplasia and the most frequent hematological neoplasms in Mexico. Med Int Méx 2025; 41 (6): 343-358. https://doi.org/10.24245/mim.v41i6.9961 Guillermo José Ruiz Delgado,1 David Gómez Almaguer,2 Xavier López Karpovitch,3 Álvaro Aguayo González,4 Eucario…
Tegoprazan: Evidence and usefulness in clinical practice of the management of acid-related diseases. Med Int Méx 2025; 41 (4): 234-249. https://doi.org/10.24245/mim.v41iAbril.9653 José María Remes Troche, José Luis Vargas Basurto Laboratorio de Fisiología…